SMS Lifesciences India Limited (SMSLIFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SMS Lifesciences India Limited (SMSLIFE) has a cash flow conversion efficiency ratio of 0.161x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs340.55 Million ≈ $3.68 Million USD) by net assets (Rs2.12 Billion ≈ $22.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SMSLIFE net asset quality index to measure how much of total assets are equity-financed.
SMS Lifesciences India Limited - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how SMS Lifesciences India Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SMSLIFE cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
SMS Lifesciences India Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SMS Lifesciences India Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Defiance Silver Corp
V:DEF
|
-0.010x |
|
Amicogen Inc
KQ:092040
|
-0.027x |
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
0.092x |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
0.023x |
|
DKLS Industries Bhd
KLSE:7528
|
0.017x |
|
Exel Composites Oyj
HE:EXL1V
|
0.102x |
|
Unibios Holdings S.A
AT:BIOSK
|
0.017x |
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
-0.028x |
Annual Cash Flow Conversion Efficiency for SMS Lifesciences India Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of SMS Lifesciences India Limited from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of SMS Lifesciences India Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs2.12 Billion ≈ $22.93 Million |
Rs298.10 Million ≈ $3.22 Million |
0.141x | +12.00% |
| 2024-03-31 | Rs1.94 Billion ≈ $20.94 Million |
Rs243.06 Million ≈ $2.63 Million |
0.126x | +14010783.13% |
| 2023-03-31 | Rs1.64 Billion ≈ $17.74 Million |
Rs1.47K ≈ $15.89 |
0.000x | +100.00% |
| 2022-03-31 | Rs1.65 Billion ≈ $17.84 Million |
Rs-112.41 Million ≈ $-1.22 Million |
-0.068x | -125.04% |
| 2021-03-31 | Rs1.29 Billion ≈ $13.97 Million |
Rs351.70 Million ≈ $3.80 Million |
0.272x | +116.54% |
| 2020-03-31 | Rs1.16 Billion ≈ $12.52 Million |
Rs145.47 Million ≈ $1.57 Million |
0.126x | -55.44% |
| 2019-03-31 | Rs1.06 Billion ≈ $11.50 Million |
Rs299.93 Million ≈ $3.24 Million |
0.282x | +211.71% |
| 2018-03-31 | Rs884.08 Million ≈ $9.56 Million |
Rs80.00 Million ≈ $865.21K |
0.090x | -63.89% |
| 2017-03-31 | Rs808.34 Million ≈ $8.74 Million |
Rs202.60 Million ≈ $2.19 Million |
0.251x | -11.86% |
| 2016-03-31 | Rs691.28 Million ≈ $7.48 Million |
Rs196.59 Million ≈ $2.13 Million |
0.284x | -- |
About SMS Lifesciences India Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more